ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baricitinib

Also written as “Baricitinib”, “LY3009104” and “INCB028050”.

Its studies are mostly in Arthritis, Rheumatoid · Dermatitis, Atopic · Lupus Erythematosus, Systemic · COVID-19 · Arthritis, Juvenile, led by 5 companies.

Drug pageBaricitinib: every studyMany companies study it; this page follows only the 58 they lead. All 149 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Apr 12, 201958 company-led studies, 7 open or runningNext primary completion: Jul 2027

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly546 open or runningphase 4since Apr 12, 2019Aug 18, 2010Mar 2028phase 3 · NCT05723198
Galvani Bioelectronicsits history only11 open or runningno phasesince Jul 5, 2021Jul 5, 2021Jul 2027NCT05003310
Genuine Research Center, Egyptits history only10 open or runningphase 1since Aug 9, 2021Aug 9, 2021none ahead
Incepta Pharmaceuticalsits history only10 open or runningphase 3since Sep 20, 2021Sep 20, 2021none ahead
Incyteits history only10 open or runningphase 2since May 13, 2009May 13, 2009none ahead

Also a collaborator on its studies: Q2 Solutions and Horus Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Aug 18, 2010.

  1. Oct 30, 2018Phase 3 study in Dermatitis, AtopicNCT03733301 · 329 enrolled · Argentina, Australia, Austria and more
  2. Nov 14, 2018Phase 2 study in Liver Cirrhosis, BiliaryNCT03742973 · 2 enrolled · United States, Puerto Rico
  3. Dec 11, 20182 phase 3 studies in Arthritis, JuvenileNCT03773978, NCT03773965
  4. Feb 14, 2019Phase 3 study in Lupus Erythematosus, SystemicNCT03843125 · 1,147 enrolled · United States, Argentina, Australia and more
  5. Apr 1, 2019Phase 3 study in Alopecia AreataNCT03899259 · 606 enrolled · United States, Argentina, Australia and more
  6. Apr 12, 2019Phase 4 study in Arthritis, RheumatoidNCT03915964 · 2,659 enrolled · United States, Australia, Austria and more
  7. May 15, 2019Phase 3 study in Dermatitis, AtopicNCT03952559 · 516 enrolled · Argentina, Australia, Austria and more
  8. Sep 10, 2019Phase 4 study in Arthritis, RheumatoidNCT04086745 · 1,050 enrolled · United States
  9. Sep 11, 20192 phase 3 studiesNCT04088409, NCT04088396
  10. Jun 5, 2020Phase 3 study in COVID-19NCT04421027 · 1,525 enrolled · United States, Argentina, Brazil and more
  11. Aug 17, 2020Phase 3 study in Nakajo syndromeNCT04517253 · 10 enrolled · Japan
  12. Oct 8, 2021Phase 3 study in COVID-19NCT05074420 · 6 enrolled · United States, Brazil, Mexico and more
  13. Feb 3, 2023Phase 3 study in AlopeciaNCT05723198 · 595 planned · United States, Argentina, Australia and more
  14. Oct 27, 20252 phase 3 studies in Diabetes Mellitus, Type 1NCT07222332, NCT07222137

Ahead

  1. Mar 2028Primary completion: phase 3 study in AlopeciaNCT05723198
  2. Jul 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07222332
  3. Jul 2031Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07222137
  4. Jul 2031Primary completion: phase 3 study in Arthritis, JuvenileNCT03773965

TargetBeta

JAK1 →JAK2 →read by rule
“An orally bioavailable inhibitor of Janus kinases 1 and 2 (JAK1/2), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
filgotinibruleLakefront Biotherapeutics NVphase 346
jaktinibruleSuzhou Zelgen Biopharmaceuticalsphase 331
delgocitinibruleLEO Pharmaphase 321
momelotinibruleGlaxoSmithKlinephase 317

Studies

All 54 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07222332Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more3RecruitingJul 2028300
NCT07222137Diabetes Mellitus, Type 1 · United States, Australia, Belgium and more3RecruitingJul 2031150
NCT05723198Alopecia · United States, Argentina, Australia and more3RecruitingMar 2028595
NCT05074420COVID-19 · United States, Brazil, Mexico and more3TerminatedSep 5, 20246
NCT04517253Nakajo syndrome · Japan3TerminatedApr 4, 202310
NCT04421027COVID-19 · United States, Argentina, Brazil and more3CompletedFeb 12, 20211,525
NCT04088409Uveitis · France, Germany, Italy and more3Active, not recruitingJul 17, 202330
NCT04088396Arthritis, Juvenile · Argentina, Belgium, Brazil and more3Active, not recruitingOct 202658
NCT04086745Arthritis, Rheumatoid · United States4CompletedMay 19, 20251,050
NCT03952559Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedApr 24, 2022516
NCT03915964Arthritis, Rheumatoid · United States, Australia, Austria and more4CompletedMay 28, 20252,659
NCT03899259Alopecia Areata · United States, Argentina, Australia and more3CompletedJan 24, 2021606
NCT03843125Lupus Erythematosus, Systemic · United States, Argentina, Australia and more3TerminatedApr 1, 20221,147
NCT03773978Arthritis, Juvenile · Argentina, Australia, Austria and more3CompletedJan 26, 2022220
NCT03773965Arthritis, Juvenile · Argentina, Australia, Austria and more3RecruitingJul 2031190
NCT03742973Liver Cirrhosis, Biliary · United States, Puerto Rico2TerminatedSep 26, 20192
NCT03733301Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedJul 29, 2019329
NCT03616964Lupus Erythematosus, Systemic · United States, Argentina, Chile and more3CompletedSep 24, 2021778
NCT03616912Lupus Erythematosus, Systemic · United States, Australia, Austria and more3TerminatedNov 1, 2021830
NCT03570749Alopecia Areata · United States, Japan, Mexico and more3CompletedFeb 2, 2021784
NCT03559270Dermatitis, Atopic · United States, Canada, Puerto Rico3TerminatedOct 14, 2021374
NCT03435081Dermatitis, Atopic · United States, Canada, Puerto Rico3CompletedDec 9, 2019440
NCT03428100Dermatitis, Atopic · Austria, Belgium, Brazil and more3CompletedNov 25, 2019463
NCT03334435Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedSep 21, 20201,645
NCT03334422Dermatitis, Atopic · Argentina, Australia, Austria and more3CompletedDec 12, 2018615
NCT03334396Dermatitis, Atopic · Czechia, Denmark, France and more3CompletedDec 6, 2018660
NCT03212638Healthy · Singapore1CompletedJul 31, 201742
NCT02758613Healthy · China1CompletedJul 201633
NCT02708095Lupus Erythematosus, Systemic · United States, Argentina, Austria and more2CompletedOct 12, 2017314
NCT02576938Dermatitis, Atopic · United States, Japan2CompletedFeb 2017124
NCT02340104Healthy Volunteers · United Kingdom1CompletedFeb 20158
NCT02265705Arthritis, Rheumatoid · Argentina, Brazil, China3CompletedMay 2017290
NCT02263911Healthy Participants · Japan1CompletedDec 201416
NCT01968057Healthy Volunteers · United Kingdom1CompletedDec 201318
NCT01937026Healthy Volunteers · United Kingdom1CompletedNov 201318
NCT01925144Healthy Volunteers · United Kingdom1CompletedNov 201330
NCT01924299Healthy Volunteers · United Kingdom1CompletedNov 201336
NCT01910311Healthy Volunteers · United Kingdom1CompletedOct 201318
NCT01896726Healthy Volunteers · United Kingdom1CompletedOct 201320
NCT01885078Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedNov 12, 20202,877
NCT01870388Liver Diseases · United States1CompletedJul 201316
NCT01859078Healthy Volunteers · United Kingdom1CompletedAug 201328
NCT01721057Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedSep 2014684
NCT01721044Arthritis, Rheumatoid · United States, Argentina, Australia and more3CompletedJun 2014527
NCT01711359Arthritis, Rheumatoid · United States, Argentina, Austria and more3CompletedFeb 2015588
NCT01710358Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedMar 20151,307
NCT01683409Diabetic Nephropathies · United States, Japan, Mexico and more2CompletedSep 2014130
NCT01536951Healthy Participants · United States1CompletedMay 201362
NCT01490632Psoriasis · United States, Canada, Japan and more2CompletedDec 2012271
NCT01469013Arthritis, Rheumatoid · Japan2CompletedNov 2012145
NCT01398475Arthritis, Rheumatoid · Singapore1CompletedSep 201115
NCT01299285Healthy Volunteers · United States1CompletedMar 20116
NCT01247350Healthy Volunteer · United States1CompletedApr 201134
NCT01185353Arthritis, Rheumatoid · United States, Croatia, Czechia and more2CompletedDec 2011301

How it is read

Names in the registry

  • “Baricitinib”, 53 entries
  • “LY3009104”, 5 entries
  • “INCB028050”, 3 entries
  • “Barcimiant”, 1 entry
  • “Baricitinib suspension”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.